Research Topics
Genomes and Genes
Species | Stephan TarganSummaryAffiliation: Cedars-Sinai Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot studyWilliam S Mow
Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, California 90048, USA
Dig Dis Sci 49:1280-6. 2004..Although not statistically significant, these results support further testing to determine whether predominant serum reactivity to certain bacterial antigens may be a marker for efficacious use of antibiotics...
IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A proteinKathrin S Michelsen
Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
PLoS ONE 4:e4719. 2009..TL1A and its receptor DR3 are up-regulated during chronic intestinal inflammation in ulcerative colitis and Crohn's disease (CD). TL1A gene haplotypes increase CD susceptibility in Japanese, European, and US cohorts...- High-frequency haplotypes in the X chromosome locus TLR8 are associated with both CD and UC in femalesMasayuki Saruta
Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center and the UCLA School of Medicine, Los Angeles, California 90048, USA
Inflamm Bowel Dis 15:321-7. 2009..Interestingly, TLR8 is located on the X chromosome and inflammatory bowel disease (IBD) has been associated with abnormalities of the X chromosome. The aim was to test whether TLR8 haplotypes are associated with IBD... - MAGI2 genetic variation and inflammatory bowel diseaseDermot P B McGovern
Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Inflamm Bowel Dis 15:75-83. 2009..Our aim was to test MAGI2 variants for association with IBD and also their role in determining intermediate hereditary phenotypes defined by antibody production to microbial antigens... - Ex vivo induction of mRNA in human whole blood as a new platform of drug and dietary supplement developmentMasato Mitsuhashi
Hitachi Chemical Research Center Inc, Irvine, CA, USA
Pharm Res 25:1116-24. 2008..This model system was applied to study various fields of drug development... - TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targetsStephanie C Heidemann
Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, 8700 Beverly Blvd, D4063, Los Angeles, CA, 90048, USA
J Clin Immunol 30:531-8. 2010..Its ligand, death domain receptor 3 (DR3), is induced by activation on T and NK cells. Although IL-12/IL-18 induces DR3 expression on most NK cells, addition of TL1A minimally increases IFN-gamma production... - Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's diseaseStephan R Targan
Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
Gastroenterology 128:2020-8. 2005.... - Defects in mucosal immunity leading to ulcerative colitisStephan R Targan
Division of Gastroenterology, Inflammatory Bowel Disease Center, Immunobiology Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Immunol Rev 206:296-305. 2005..The way in which this response affects the ultimate cascade of inflammatory events has yet to be determined... - Natalizumab for the treatment of active Crohn's disease: results of the ENCORE TrialStephan R Targan
Inflammatory Bowel Disease Center and Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Gastroenterology 132:1672-83. 2007..A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease... - Inflammatory bowel disease diagnosis, evaluation and classification: state-of-the art approachStephan R Targan
Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
Curr Opin Gastroenterol 23:390-4. 2007..This review will describe the most recent advances and discuss promising pathways for therapeutic discovery... - Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activationH Takedatsu
Division of Gastroenterology, Inflammatory Bowel Disease Center, Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Gut 58:60-7. 2009..Our aim was to conduct a linkage study using expression of anti-CBir1, anti-I2, anti-OmpC and ASCA as quantitative traits... - Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosisPhillip Fleshner
Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 6:561-8. 2008..The aim of this study was to assess associations of preoperative perinuclear antineutrophil cytoplasmic antibody (pANCA) and anti-CBir1 flagellin on AP or CP development... - Association of antibody responses to microbial antigens and complications of small bowel Crohn's diseaseWilliam S Mow
Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Gastroenterology 126:414-24. 2004.... 
Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease?Evan C White
Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Dis Colon Rectum 55:563-8. 2012..Unplanned hospital readmission is considered to be an index of quality surgical care...- Rigorous histopathological assessment of the colectomy specimen in patients with inflammatory bowel disease unclassified does not predict outcome after ileal pouch-anal anastomosisYosef Nasseri
Cedars Sinai Medical Center, Los Angeles, California, USA
Am J Gastroenterol 105:155-61. 2010..We evaluated whether any histopathological feature was associated with an adverse postoperative outcome... - Preoperative wireless capsule endoscopy does not predict outcome after ileal pouch-anal anastomosisZuri Murrell
Division of Colon and Rectal Surgery, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
Dis Colon Rectum 53:293-300. 2010..This study examined the value of preoperative wireless capsule endoscopy in predicting outcome of ileal pouch-anal anastomosis in patients with ulcerative colitis or indeterminate colitis... - Increased immune reactivity predicts aggressive complicating Crohn's disease in childrenMarla C Dubinsky
Department of Pediatrics, IBD Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 6:1105-11. 2008..The aims of this study were to determine whether immune responses and/or CARD15 variants are associated with complicated disease phenotypes and predict disease progression... - A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosisPhillip Fleshner
Division of Colon and Rectal Surgery, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 5:952-8; quiz 887. 2007..The aim of this study was to identify important clinical risk factors associated with AP or CP... - LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signalingOffer Cohavy
Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
J Immunol 174:646-53. 2005..Quantitative analysis of LIGHT mRNA in a cohort of inflammatory bowel disease patients indicated elevated expression in biopsies from small bowel and from inflamed sites, implicating LIGHT as a mediator of mucosal inflammation... - Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigensCarol J Landers
Cedars-Sinai Medical Center Inflammatory Bowel Disease Center, Los Angeles, California, USA
Gastroenterology 123:689-99. 2002..CONCLUSIONS: Rather than global loss of tolerance, there seem to be patient subsets with differing responses to selected microbial and autoantigens... - A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi JewsKazuhito Sugimura
Division of Medical Genetics and Inflammatory Bowel Disease Research Center, Department of Medicine, Steven Spielberg Pediatric Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Am J Hum Genet 72:509-18. 2003..In Ashkenazi Jews, unrecognized population-specific predisposing factor(s) exist on the 268S-JW1 haplotype at the IBD1 locus. This factor may contribute to the higher risk for CD in Ashkenazi Jews as compared with non-Jews... - Enhanced CBir1-specific innate and adaptive immune responses in Crohn's diseaseChong Shen
Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Inflamm Bowel Dis 14:1641-51. 2008..Our aim was to determine whether CBir1 stimulates innate and antigen-specific T-cell responses in CD. We demonstrate that CBir1 enhanced IL-6 and IL-1beta production by peripheral blood (PB) monocytes... - TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activationHidetoshi Takedatsu
Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Gastroenterology 135:552-67. 2008..Expression of TL1A is increased in the mucosa of Crohn's disease patients and murine models of ileitis. The aim of this study was to determine the possible role of TL1A in chronic intestinal inflammation... - Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progressionMarla C Dubinsky
Department of Pediatrics, Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
Am J Gastroenterol 101:360-7. 2006.... - NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relativesShane M Devlin
Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Gastroenterology 132:576-86. 2007..The aim of our study was to determine if defects in innate immunity are similarly associated with increased adaptive immune responses to microbial antigens in Crohn's disease patients... - Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammationJohn L Prehn
Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
Clin Immunol 112:66-77. 2004..Expression of TL1A and its receptor DR3 by lamina propria mononuclear cells (LPMC) could have significant influence on the severity of mucosal inflammation... - Genetic epistasis of IL23/IL17 pathway genes in Crohn's diseaseDermot P B McGovern
Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Inflamm Bowel Dis 15:883-9. 2009..Genetic variants in the IL23R and IL12B have been associated with CD susceptibility. We investigated 10 genes within the IL23/IL17 pathway in a case-control study of 763 CD cases and 254 healthy controls... - IL-23 receptor (IL-23R) gene protects against pediatric Crohn's diseaseMarla C Dubinsky
Department of Pediatrics, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
Inflamm Bowel Dis 13:511-5. 2007..It is unknown whether IL-23R is associated with IBD in children. The aim was to examine the association of IL-23R with susceptibility to IBD in pediatric patients... - CD56 marks an effector T cell subset in the human intestineOffer Cohavy
Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
J Immunol 178:5524-32. 2007..Our findings associate CD56+ T cells with the intestinal immune compartment and suggest a putative effector function in human mucosal immunity... - TLR8-mediated activation of human monocytes inhibits TL1A expressionMasayuki Saruta
Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Eur J Immunol 39:2195-202. 2009..Our data demonstrate for the first time a direct interaction between TLR and TL1A signaling pathways. TLR8 activation may be an important, novel pathway for targeted treatment of Th1-mediated diseases, such as CD... - Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's diseaseAndrew Ippoliti
Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA, USA
Inflamm Bowel Dis 16:1279-85. 2010.... - Surgical outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn's diseaseQuy Le
Division of Colon and Rectal Surgery Division of Gastroenterology, and the Division of Pediatric Gastroenterology Division of Medical Genetics, Departments of Surgery, Pediatrics and Medicine, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California
Inflamm Bowel Dis 19:30-6. 2013..Crohn's disease (CD) is considered a contraindication to ileal pouch-anal anastomosis (IPAA). In this study, we compare outcomes of CD and ulcerative colitis (UC) patients undergoing IPAA... - High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapyWilliam S Mow
Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Clin Gastroenterol Hepatol 2:309-13. 2004..Evaluation for TB risks should include not only a TST, but also a detailed history of travel, TB exposures, and such symptoms as chronic cough and weight loss, and a chest radiograph should be considered... - Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cellsDavid Q Shih
Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Eur J Immunol 39:3239-50. 2009..Our findings suggest a role for TL1A in pro-inflammatory APC-T cell interactions and implicate TL1A in host responses to enteric microorganisms... - Antibodies to I2 predict clinical response to fecal diversion in Crohn's diseaseJacob Spivak
Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Inflamm Bowel Dis 12:1122-30. 2006..CONCLUSION: Expression of I2 antibodies against a bacterial antigen of Pseudomonas fluorescens was highly associated with clinical response to fecal diversion in CD patients... - Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-D-glucose and positron emission tomographySarah Brewer
Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
Gastroenterology 135:744-55. 2008..However, there is limited understanding of the biologic basis of mucosal FDG uptake... - Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammationThomas Hui
Division of Colon and Rectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
Dis Colon Rectum 48:1254-62. 2005.... - A genome-wide association study identifies IL23R as an inflammatory bowel disease geneRichard H Duerr
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, University of Pittsburgh, University of Pittsburgh Medical Center Presbyterian, Mezzanine Level, C Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA
Science 314:1461-3. 2006..These results and previous studies on the proinflammatory role of IL-23 prioritize this signaling pathway as a therapeutic target in inflammatory bowel disease... - Future biologic targets for IBD: potentials and pitfallsGil Y Melmed
Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, 8635 West 3rd Street, 960 W Los Angeles, CA 90048, USA
Nat Rev Gastroenterol Hepatol 7:110-7. 2010..Future biologic drug development will benefit from the early identification of subsets of patients who are most likely to respond to therapy by use of biological markers of genetic susceptibility or immunologic susceptibility... - Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel diseaseWilliam S Mow
Inflammatory Bowel Disease Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 2:31-40. 2004.... - Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel diseaseStephen A Geller
Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Am J Surg Pathol 28:1204-11. 2004..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease... - Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control studyGil Y Melmed
Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, California, USA
Clin Gastroenterol Hepatol 5:602-8; quiz 525. 2007..Identification of predictors of a diagnostic change could potentially impact the management of patients with colonic inflammation. Our aim was to characterize clinical and serologic predictors of a change in diagnosis from UC to CD... - Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitisGil Y Melmed
Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Dis Colon Rectum 51:100-8. 2008..Preoperative predictors for Crohn's disease post-ileal pouch-anal anastomosis have not been prospectively defined... - Genome-wide association identifies multiple ulcerative colitis susceptibility lociDermot P B McGovern
Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
Nat Genet 42:332-7. 2010..These data implicate approximately 30 loci in ulcerative colitis, thereby providing insight into disease pathogenesis... - CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profileKonstantinos A Papadakis
Burns and Allen Research Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
J Immunol 171:159-65. 2003..Studies on the cytokine profile and Ag specificity of this cell subset could provide important insight into small intestinal immune-mediated diseases and oral tolerance in humans... - LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestineOffer Cohavy
Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
J Immunol 173:251-8. 2004..Taken together, these findings suggest LIGHT-herpesvirus entry mediator mediated signaling as an important immune regulatory mechanism in mucosal inflammatory responses... - Genetic predictors of medically refractory ulcerative colitisTalin Haritunians
Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Inflamm Bowel Dis 16:1830-40. 2010..The aim of this study was to use a genome-wide association study (GWAS) in a well-characterized cohort of UC patients to identify genetic variation that contributes to MR-UC... - Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associationsKonstantinos A Papadakis
Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California, USA
Inflamm Bowel Dis 13:524-30. 2007..We examined the association between anti-CBir1 and clinical phenotypes and NOD2 variants in a large cohort of adult CD patients... - Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytesKonstantinos A Papadakis
Burns and Allen Research Institute, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90048, USA
J Immunol 174:4985-90. 2005.... - Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosaKonstantinos A Papadakis
Inflammatory Bowel Disease Center and Burns and Allen Research Institute, Los Angeles, CA 90048, USA
Inflamm Bowel Dis 10:778-88. 2004..Activation-dependent receptor regulation and alteration in receptor-bearing cells, primarily in MLN draining inflamed intestinal tissue, suggest an important role for this T-cell subset in the pathogenesis of human IBD... - A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitisEvan White
Division of Colon and Rectal Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
Dis Colon Rectum 53:987-94. 2010..We prospectively compared the outcomes of ileal pouch-anal anastomosis in colitis patients with backwash ileitis and colitis patients without backwash ileitis... - Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel diseaseMarla C Dubinsky
Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
Inflamm Bowel Dis 16:1357-66. 2010.... - Immunogenetic phenotypes in inflammatory bowel diseaseMarla C Dubinsky
Department of Pediatrics, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
World J Gastroenterol 12:3645-50. 2006.... - Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel diseaseGil Y Melmed
Department of Medicine, Cedars Sinai Medical Center, University of California, Los Angeles, California 90048, USA
Am J Gastroenterol 105:148-54. 2010..We aimed to assess the impact of immunosuppression on immune responses to pneumococcal vaccination in patients with IBD... - Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's diseaseMaria T Abreu
Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Gastroenterology 123:679-88. 2002..NOD2 gene mutations in CD have been described recently and may alter innate immune responses. We hypothesized that NOD2 mutations may be associated with distinct phenotypic expressions of CD... - Current limitations of IBD treatment: where do we go from here?Stephan R Targan
Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite D4063, Los Angeles, CA 90048, USA
Ann N Y Acad Sci 1072:1-8. 2006.... - Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's diseaseDermot P B McGovern
Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Hum Mol Genet 19:3468-76. 2010..001). These findings strongly implicate this locus in CD susceptibility and highlight the role of the mucus layer in the development of CD... - IL23R haplotypes provide a large population attributable risk for Crohn's diseaseKent D Taylor
Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Inflamm Bowel Dis 14:1185-91. 2008..The aim of this work was to estimate the total contribution of this gene to CD risk test using a haplotype approach... - B lymphocyte-induced maturation protein-1 contributes to intestinal mucosa homeostasis by limiting the number of IL-17-producing CD4+ T cellsSoofia Salehi
F Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
J Immunol 189:5682-93. 2012..Collectively, the results described here establish a new role for Blimp-1 in regulating IL-17 production in vivo... - Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologistsBrennan M R Spiegel
Veteran s Administration Greater Los Angeles Healthcare System, Los Angeles, California, USA
Clin Gastroenterol Hepatol 7:168-74, 174.e1. 2009..We performed a national vignette survey to measure variations in decision-making in areas of controversy... - Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's diseaseLing Mei
Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
Gastroenterology 130:1078-85. 2006..That UC patients in mixed families had a higher response to OmpC than those in UC-only families indicates pathophysiologic heterogeneity within UC... - Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprineMarla C Dubinsky
Department of Medicine, Division of Gastroenterology, Cedars-Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
Am J Gastroenterol 98:1058-63. 2003..Despite these favorable results, candidates for 6-TG should be selected with caution, and its use should be reserved for IBD patients well informed about potential toxicities... - TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cellsKonstantinos A Papadakis
Cedars-Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
J Immunol 172:7002-7. 2004..Our data suggest that TL1A/DR3 pathway plays an important role in the augmentation of cytokine-induced IFN-gamma production in T cells and that DR3 expression is differentially regulated by IL-12/IL-18 in T cells and NK cells... - Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's diseaseMasayuki Saruta
Inflammatory Bowel Disease Center and Immunobiology Institute, Division of Colorectal Surgery, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
J Immunol 178:3293-300. 2007..Our data indicate that CCR9(+) T cells in SB CD are proinflammatory and support the rationale for the use of CCR9 antagonists for the treatment of human SB CD... - Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's diseaseMaria T Abreu
Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, New York, NY, USA
J Clin Gastroenterol 40:55-63. 2006..Studies of longer duration are needed to assess the effect of infliximab on bone mineral density... - Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?Stefanie J Schluender
Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8737 Beverly Boulevard, Suite 101, Los Angeles, California 90048, USA
Dis Colon Rectum 50:1747-53. 2007..This study was designed to compare short-term complications in patients with ulcerative colitis who were treated with and without infliximab before colectomy... - A pilot study of adalimumab in infliximab-allergic patientsAdrienne Youdim
Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
Inflamm Bowel Dis 10:333-8. 2004..Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab... - Ustekinumab induction and maintenance therapy in refractory Crohn's diseaseWilliam J Sandborn
Division of Gastroenterology, University of California San Diego, La Jolla, California 92093 0956, USA
N Engl J Med 367:1519-28. 2012..In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown... - Recent advances in IBD pathogenesis: genetics and immunobiologyDavid Q Shih
Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Suite D4059, Los Angeles, CA 90048, USA
Curr Gastroenterol Rep 10:568-75. 2008..It focuses on advances in our understanding of IBD from the past year, including advances in genetics and immunobiology... - A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitisZuri A Murrell
Department of Surgery, Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Dis Colon Rectum 52:872-8. 2009..The aim of this study was to prospectively evaluate the long-term outcome of ileal pouch-anal anastomosis in a closely monitored cohort of patients with ulcerative colitis or indeterminate colitis... - Case report: evidence for transplacental transfer of maternally administered infliximab to the newbornEric A Vasiliauskas
Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Clin Gastroenterol Hepatol 4:1255-8. 2006..As a result of heightened maternal concern triggered by recent labeling changes, infliximab levels were measured in the newborn of a mother treated with infliximab... - Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximabKonstantinos A Papadakis
Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, 8631 W. Third Street, Suite 430E, Los Angeles, CA 90048, USA
Am J Gastroenterol 100:75-9. 2005..CONCLUSIONS: Our preliminary data suggest that adalimumab may be a safe and effective therapy for patients with CD who have experienced an attenuated response to infliximab... - CD2 mediates activation of the IFN-gamma intronic STAT binding region in mucosal T cellsRivkah Gonsky
Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Eur J Immunol 33:1152-62. 2003..Thus, these results indicate that both common as well as unique molecular mechanisms are involved in CD2 signaling and activation of the STAT pathway in LP T cells which are critical for regulation of IFN-gamma expression in the gut... - Patients with inflammatory bowel disease are at risk for vaccine-preventable illnessesGil Y Melmed
Department of Medicine, Division of Gastroenterology, Cedars-Sinai Medical Center Los Angeles, California 90048, USA
Am J Gastroenterol 101:1834-40. 2006..Efforts to improve immunization status among patients with IBD and other chronic, immune-mediated conditions are needed... - Immunopathogenesis of inflammatory bowel diseaseDavid Q Shih
Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
World J Gastroenterol 14:390-400. 2008.... - Molecular approaches to the role of the microbiota in inflammatory bowel diseaseCharles O Elson
Division of Gastroenterology and Hepatology, The University of Alabama Birmingham, 633 Zeigler Research Building, 703 S 19th Street, Birmingham, AL 35294 0007, USA
Ann N Y Acad Sci 1072:39-51. 2006..Previously unknown microbial flagellins were the dominant cluster of antigens identified. About half of the sera from patients with Crohn's disease have IgG antibodies to these flagellins... - Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotypeIan D R Arnott
Gastrointestinal Unit, University of Edinburgh Department of Medical Sciences, School of Clinical and Molecular Medicine, Western General Hospital, Edinburgh EH4 2XU, UK
Am J Gastroenterol 99:2376-84. 2004..We aimed to assess the frequency of anti-OmpC, anti-I2, ASCA, and pANCA, in an independent Scottish CD cohort, establish phenotypic associations, and compare with a U.S. cohort... - Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesisJohn D Rioux
Université de Montréal and the Montreal Heart Institute, Research Center, 5000 rue Belanger, Montreal, Quebec H1T 1C8, Canada
Nat Genet 39:596-604. 2007..Together, these findings suggest that autophagy and host cell responses to intracellular microbes are involved in the pathogenesis of Crohn disease... - State of the art: IBD therapy and clinical trials in IBDKim L Isaacs
University of North Carolina, Chapel Hill, North Carolina, USA
Inflamm Bowel Dis 11:S3-12. 2005..The number of products under development and continued investigations into the pathogenesis of IBD emphasize the need to expand clinical research efforts in IBD... - TNFSF15 is an ethnic-specific IBD geneYoana Picornell
Medical Genetics Institute, Cedars Sinai Medical Center Los Angeles, California, USA
Inflamm Bowel Dis 13:1333-8. 2007..The aim was to confirm the association between TNFSF15 high- and low-risk haplotypes and IBD in a Caucasian population... - Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and predictionPeggy Vandewalle-El Khoury
INSERM, U799, Lille, France
Am J Gastroenterol 103:949-57. 2008.... - Bacterial flagellin is a dominant antigen in Crohn diseaseMichael J Lodes
Corixa Corp, Seattle, Washington, USA
J Clin Invest 113:1296-306. 2004.... - Ex vivo simulation of IgG Fc and T-cell receptor functions: an application to inflammatory bowel diseaseMasato Mitsuhashi
Hitachi Chemical Research Center, Inc, Irvine, California, USA
Inflamm Bowel Dis 14:1061-7. 2008..Human leukocyte IgG Fc receptors (FcgammaR) and T-cell receptors (TCR) are primary molecules involved in inflammatory and immune pathways... - 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel diseaseMarla C Dubinsky
Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
Gastroenterology 122:904-15. 2002..The objectives of this study were to determine whether dose escalation optimizes both 6-TGN levels and efficacy in patients failing therapy because of subtherapeutic 6-TGN levels and its effect on TPMT... - Certolizumab pegolGil Y Melmed
Nat Rev Drug Discov 7:641-2. 2008..In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies... - Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's diseaseKonstantinos A Papadakis
Gastroenterology 124:583. 2003 - Challenges in IBD Research: updating the scientific agendasCharles O Elson
Division of Gastroenterology, Inflammatory Bowel Disease Center, University of Alabama at Birmingham, USA
Inflamm Bowel Dis 9:137-53. 2003 - 6-thioguanine can cause serious liver injury in inflammatory bowel disease patientsMarla C Dubinsky
Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8635 West Third Street, Suite 1165W, Los Angeles, California 90048, USA
Gastroenterology 125:298-303. 2003..The aim of this study was to describe the association between 6-TG and NRH in IBD... - The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel diseaseRobin Matuk
Department of Medicine, Division of Gastroenterology, Cedars-Sinai Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
Inflamm Bowel Dis 10:352-6. 2004..Treatment with COX-2 inhibitors is associated with a high incidence of exacerbation of the underlying IBD and GI-related complications... - Enhancer role of STAT5 in CD2 activation of IFN-gamma gene expressionRivkah Gonsky
Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
J Immunol 173:6241-7. 2004..This report is the first to describe CD2-mediated activation of STAT5 and supports STAT5 involvement in regulation of IFN-gamma expression... - Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitisAderet Okon
Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
Am Surg 71:821-6. 2005..03). The incidence of CP was significantly higher after IPAA in UC patients having thrombocytosis before surgery compared to UC patients having a normal platelet count before surgery... - The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cellsJohn L Prehn
Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
J Immunol 178:4033-8. 2007..Furthermore, we demonstrate that TL1A production in monocytes leads to enhancement of T cell responses. The induction of TL1A on APCs via specific pathway stimulation suggests a role for TL1A in Th1 responses to pathogens, and in CD... - Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's diseaseJeffrey C Barrett
Bioinformatics and Statistical Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
Nat Genet 40:955-62. 2008..The expanded molecular understanding of the basis of this disease offers promise for informed therapeutic development... - Biologic therapy of inflammatory bowel diseaseWilliam J Sandborn
Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Gastroenterology 122:1592-608. 2002..Based on the early successes of infliximab, CDP571 and natalizumab, it seems certain that biologic therapy will play an important role in the future treatment of inflammatory bowel disease...
Research Grants
- Role of TL1A in Severity of Crohn's Disease InflammationStephan R Targan; Fiscal Year: 2010....
- IBD--MUCOSA-SPECIFIC REGULATION OF IFN-GAMMA PRODUCTIONStephan Targan; Fiscal Year: 2005..abstract_text> ..
- IBD:TNF-alpha and Crohn's Disease Mucosal InflammationStephan Targan; Fiscal Year: 2007..abstract_text> ..
- TNF ALPHA AND CROHNS DISEASE MUCOSAL INFLAMMATIONStephan Targan; Fiscal Year: 2003..Furthermore, it will allow studies to define new targets for therapeutic approaches aimed at selectively downregulating the TNF-alpha mediated, enhancement of Th1 responses in Crohn's mucosa. ..
- ROLE OF ACTIVATED T CELLS IN GUT INJURYStephan Targan; Fiscal Year: 1993..2. Define the regulation of TNF-alpha and IFN-gamma transcription, production and release from mucosal T-cells. 3. Determine the mechanism of TNF-alpha and IFN-gamma synergism of epithelial cell cytoxicity...
- IBD--ROLE OF ACTIVATED T-CELLS IN GUT INJURYStephan Targan; Fiscal Year: 2000..3). The constitutive composition of the jun and jun/fos AP-1 in LP-like and LPT cells and whether activation by CD2 and/or CD28 results in differences in the expression in composition of these dimeric proteins. ..